Tradestie Institutional Equity Comparison Engine

IOVA vs BIIB โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

BIIB Overall Edge

BIIB Captures Institutional Edge (3โ€“1 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Biogen Inc. Common Stock (BIIB) driven by superior Valuation, Growth & Margin, Options & Structure while IOVA counters with relative strength in Momentum & Technical. Fundamentally, IOVA trades at N/M Forward P/E with -60.8% operating margin (+80.1% YoY revenue) versus BIIB at 15.6x Forward P/E and 23.5% operating margin (+10.6% YoY). In options structure, IOVA sits in BREAKDOWN (25th %ile IV; Dealer Gamma Walls on Pro) against BIIB sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner BIIB
IOVA N/M vs BIIB 15.6x Fwd P/E
Growth & Margin Winner BIIB
Op Margin -60.8% vs 23.5% ยท YoY +80.1% vs +10.6%
Momentum & Technical Winner IOVA
1Y +216.5% vs +53.4% ยท 52W Pos 42% vs 92%
Options & Structure Winner BIIB
BREAKDOWN (25th %ile IV) vs CONSOLIDATION (6th %ile IV)
IOVA NASDAQ
Iovance Biotherapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$7.63
-1.71% 1D
Market Cap $3.5B
1M Return -44.0%
1Y Return +216.47%
Forward P/E N/M
Unified AI Score
70.4 / 100 BUY
Tech 80.0 Fund 70.0 Flow 70.0 Mom 70.0
BIIB NASDAQ
Biogen Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$252.72
-0.27% 1D
Market Cap $37.0B
1M Return +8.63%
1Y Return +53.41%
Forward P/E 15.6x
Unified AI Score
50.2 / 100 HOLD
Tech 45.0 Fund 52.0 Flow 64.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: IOVA +216.47% BIIB +53.41% Spread: +163.06 pp (IOVA Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period IOVA Revenue BIIB Revenue IOVA Op. Margin BIIB Op. Margin Margin Edge
FY2018 N/A $13.4B N/A 43.8% BIIB
FY2019 N/A $14.4B N/A 49.0% BIIB
FY2020 N/A $13.4B N/A 33.8% BIIB
FY2021 N/A $11.0B N/A 25.9% BIIB
FY2022 N/A $10.2B N/A 29.9% BIIB
FY2023 $0M $9.84B -38735.0% 11.8% BIIB
FY2024 $160M $9.68B -240.9% 16.9% BIIB
FY2025 $260M $9.89B -153.1% 13.1% BIIB

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: IOVA (2) vs BIIB (8)
Institutional Metric IOVA BIIB Criterion Row Winner
Market Capitalization Scale $3.5B $37.0B Larger Scale BIIB
Trailing P/E Ratio Valuation N/M 109.9x Lower Multiple BIIB
Forward P/E Ratio Valuation N/M 15.6x Lower Multiple BIIB
Revenue Growth (YoY) Growth +80.1% +10.6% Higher Growth IOVA
Operating Margin (TTM) Profitability -60.8% 23.5% Higher Margin BIIB
Net Profit Margin Profitability -58.2% 3.4% Higher Margin BIIB
Return on Equity (ROE) Capital Efficiency -29.1% 1.9% Higher ROE BIIB
52-Week Range Position Momentum 42% ($2โ€“$15) 92% ($160โ€“$261) Stronger Trend BIIB
Beta / 30D Volatility Risk Regime 1.58ฮฒ ยท 144% Vol 0.27ฮฒ ยท 36% Vol Lower Realized Risk BIIB
Unified Institutional Score Composite Signal 70.4 / 100 (BUY) 50.2 / 100 (HOLD) Higher Composite IOVA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full IOVA vs BIIB Buy Guide
IOVA BREAKDOWN
33d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 25th %ile
IV Regime Compressed (<25th %ile)
Live IOVA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
BIIB CONSOLIDATION
17d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live BIIB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither IOVA nor BIIB registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.